Immune checkpoint inhibitors (ICIs), such as anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies, play a crucial role in reactivating the antitumor immune response by blocking inhibitory signals that allow tumor cells to evade immune surveillance [1,3]. The gene discussed is CD274; the disease is neoplasm.